+
Site Tour

Search

Showing 71 - 80 of 447 results.

  • Overview

    *For 27 mm valve size, measured from the farthest point of the cuff. 0 *There is no clinical data currently available that evaluates the long-term impact of anticalcification tissue treatment in…
  • Clinical Data

    EXCELLENT OUTCOMES IN CLINICAL TRIAL RESULTS 0 FIND OUT MORE: Clinical trials  CLINICAL INSIGHTS 0 30-DAY NAVITOR™1,2 N=120 EVOLUT‡ PRO3 N=60 ACURATE…
  • NAVITOR™ TAVI system features

    Large effective orifice areas.1,2 Single-digit gradients.1,2 30-day Echo Core Lab Data1,2 0 HEMODYNAMIC IMPACT Non-tapered stent and large effective orifice areas resulting in single-digit…
  • Voice of the experts

    STABLE DELIVERY. REMARKABLE PERFORMANCE. FUTURE READY.   0 STABLE DELIVERY 0 REMARKABLE PERFORMANCE 0 FUTURE READY 0 WATCH TAVI SUMMIT: TAVI SUMMIT 2024 TAVI SUMMIT 2023 0
  • Overview

    WATCH TAVI SUMMIT: TAVI SUMMIT 2024  TAVI SUMMIT 2023 0 WATCH THE LIVE CASES: LIVE CASE FROM EACTS TECHNO-COLLEGE  LIVE CASE FROM RIGSHOSPITALET COPENHAGEN 0 NAVITOR…
  • Clinical Data

    Tendyne™ TMVR improves your patients’ function and quality of life, with clinically significant improvement in a 6-minute walk test2 and Kansas City Cardiomyopathy Questionnaire (KCCQ) scores.1 The…
  • Patients who benefit

    PATIENTS WHO BENEFIT MR IS THE MOST COMMON VALVULAR HEART DISEASE AND IS SIGNIFICANTLY UNDERTREATED3 More patients are suffering from MR than any other valve disease, and only a small percentage…
  • Clinical Data

    INSPIRED BY PATIENTS. MADE POSSIBLE BY YOU. TriClip TEER has shown meaningful outcomes in both real-world and randomized clinical data. The bRIGHT study and TRILUMINATE™ Pivotal trial demonstrated…
  • Features

    The TriClip™ G4 Transcatheter Edge-to-Edge Repair System empowers you with stable navigation and precise delivery2 for complex conditions. 0 …
  • Patients who benefit

    A STATE-OF-THE-ART TREATMENT OPTION FOR PATIENTS AT HIGH RISK FOR SURGERY TriClip™ TEER is a low risk,5 minimally invasive, non-surgical treatment option for symptomatic patients with severe…

You are about to leave my-connext.com

You are now leaving my-connext.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

The content on this website is intended for healthcare professionals in EMEA with applicable health authority product registrations, excepted those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Click OK to confirm you are a healthcare professional to proceed.

OK Decline